/
Infectious Disease
HIV-1
36
Pipeline Programs↗
66
Active Trials↗
26
Companies Involved↗
HIV-1 is a moderately active landscape with 36 programs across 26 companies. The most active players are Gilead, Merck & Co., GSK. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 26
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
29 of 32 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 92% of 36 pipeline programs.
Analysis
Trial Status
264
clinical trials
Completed157 · 59%
Recruiting26 · 10%
Active, not recruiting23 · 9%
Not yet recruiting17 · 6%
Terminated17 · 6%
Unknown status15 · 6%
Other9 · 3%
Clinical Trials
Trial Activity
264 trials
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)